Secuado
Generic name: asenapine
Treatment for: Schizophrenia
Notification of a New Drug Application for HP-3070 (Transdermal Patch for the Treatment of Schizophrenia) in the U.S.
Tosu City, Saga Prefecture, December 17, 2018 - Hisamitsu Pharmaceutical Co., Ltd. (Headquarters: Tosu City, Saga Prefecture, Chairman and Chief Executive Officer (CEO): Hirotaka Nakatomi, hereinafter "Hisamitsu Pharmaceutical"), in conjunction with its U.S. subsidiary, Noven Pharmaceuticals, Inc. announces that a New Drug Application has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of HP-3070 (asenapine) transdermal system for the treatment of schizophrenia (Development code: HP-3070, generic name: asenapine, hereinafter referred to as “the investigational product”).
The investigational product is a systemic transdermal formulation developed using Hisamitsu Pharmaceutical’s Transdermal Drug Delivery System (TDDS) technology. Hisamitsu Pharmaceutical expects the investigational product to be a new option in the treatment of schizophrenia. The development of the investigational product represents Hisamitsu Pharmaceutical’s commitment to improving the lives of the community of patients who live with schizophrenia.
Source: Noven Pharmaceuticals, Inc.
Posted: December 2018
Related articles
- FDA Approves Secuado (asenapine) Transdermal System for the Treatment of Adults with Schizophrenia - October 15, 2019
Secuado (asenapine) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
